Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers
Akari Therapeutics Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live
Akari Therapeutics Releases Virtual Investor "What This Means" Segment Highlighting its Recently Granted India Patent
Akari Therapeutics Releases "Meet the Team" Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development - Oncology
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.